Article
Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
BJOG : an international journal of obstetrics and gynaecology - 1 Jun 2017
Cui R R, Wright J D, Hou J Y
Abstract excerpt
Uterine leiomyosarcoma (LMS) are rare but aggressive tumours with poor clinical outcomes regardless of stage. Most tumours are identified by histopathology at time of surgery, and pre-operative diagnosis remains a clinical challenge. Management of early-stage LMS relies on surgical resection. Cytotoxic chemotherapy remains the mainstay of therapy for advanced-stage, recurrent or metastatic LMS, and includes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.